Literature DB >> 10980131

Expression of p57(KIP2) potently blocks the growth of human astrocytomas and induces cell senescence.

A Tsugu1, K Sakai, P B Dirks, S Jung, R Weksberg, Y L Fei, S Mondal, S Ivanchuk, C Ackerley, P A Hamel, J T Rutka.   

Abstract

Astrocytic tumors frequently exhibit defects in the expression or activity of proteins that control cell-cycle progression. Inhibition of kinase activity associated with cyclin/cyclin-dependent kinase co-complexes by cyclin-dependent kinase inhibitors is an important mechanism by which the effects of growth signals are down-regulated. We undertook the present study to determine the role of p57(KIP2) (p57) in human astrocytomas. We demonstrate here that whereas p57 is expressed in fetal brain tissue, specimens of astrocytomas of varying grade and permanent astrocytoma cell lines do not express p57, and do not contain mutations of the p57 gene by multiplex-heteroduplex analysis. However, the inducible expression of p57 in three well-characterized human astrocytoma cell lines (U343 MG-A, U87 MG, and U373 MG) using the tetracycline repressor system leads to a potent proliferative block in G(1) as determined by growth curve and flow cytometric analyses. After the induction of p57, retinoblastoma protein, p107, and E2F-1 levels diminish, and retinoblastoma protein is shifted to a hypophosphorylated form. Morphologically, p57-induced astrocytoma cells became large and flat with an expanded cytoplasm. The inducible expression of p57 leads to the accumulation of senescence-associated beta-galactosidase marker within all astrocytoma cell lines such that approximately 75% of cells were positive at 1 week after induction. Induction of p57 in U373 astrocytoma cells generated a small population of cells ( approximately 15%) that were nonviable, contained discrete nuclear fragments on Hoechst 33258 staining, and demonstrated ultrastructural features characteristic of apoptosis. Examination of bax and poly-(ADP ribose) polymerase levels showed no change in bax, but decreased expression of poly-(ADP ribose) polymerase after p57 induction in all astrocytoma cell lines. These data demonstrate that the proliferative block imposed by p57 on human astrocytoma cells results in changes in the expression of a number of cell cycle regulatory factors, cell morphology, and a strong stimulus to cell senescence.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10980131      PMCID: PMC1885689          DOI: 10.1016/S0002-9440(10)64605-6

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  98 in total

1.  Ablation of the CDK inhibitor p57Kip2 results in increased apoptosis and delayed differentiation during mouse development.

Authors:  Y Yan; J Frisén; M H Lee; J Massagué; M Barbacid
Journal:  Genes Dev       Date:  1997-04-15       Impact factor: 11.361

2.  Ionizing radiation inhibits chemotherapy-induced apoptosis in cultured glioma cells: implications for combined modality therapy.

Authors:  G L Yount; D A Haas-Kogan; K S Levine; K D Aldape; M A Israel
Journal:  Cancer Res       Date:  1998-09-01       Impact factor: 12.701

3.  Chemotherapy primes malignant glioma cells for CD95 ligand-induced apoptosis up-stream of caspase 3 activation.

Authors:  A Hueber; S Winter; M Weller
Journal:  Eur J Pharmacol       Date:  1998-07-03       Impact factor: 4.432

4.  Evaluation of apoptosis in four human tumour cell lines with differing sensitivities to cisplatin.

Authors:  G P Raaphorst; J Mao; H Yang; R Goel; B Niknafs; F H Shirazi; H M Yazdi; P Rippstein; C E Ng
Journal:  Anticancer Res       Date:  1998 Jul-Aug       Impact factor: 2.480

5.  The E2F-family proteins induce distinct cell cycle regulatory factors in p16-arrested, U343 astrocytoma cells.

Authors:  P B Dirks; J T Rutka; S L Hubbard; S Mondal; P A Hamel
Journal:  Oncogene       Date:  1998-08-20       Impact factor: 9.867

6.  Enhancement of radiosensitivity of wild-type p53 human glioma cells by adenovirus-mediated delivery of the p53 gene.

Authors:  F F Lang; W K Yung; U Raju; F Libunao; N H Terry; P J Tofilon
Journal:  J Neurosurg       Date:  1998-07       Impact factor: 5.115

7.  Transforming growth factor-beta1 induces apoptotic cell death in cultured retinal endothelial cells but not pericytes: association with decreased expression of p21waf1/cip1.

Authors:  Q Yan; E H Sage
Journal:  J Cell Biochem       Date:  1998-07-01       Impact factor: 4.429

8.  Inactivation of p53 in a human ovarian cancer cell line increases the sensitivity to paclitaxel by inducing G2/M arrest and apoptosis.

Authors:  F Vikhanskaya; S Vignati; P Beccaglia; C Ottoboni; P Russo; M D'Incalci; M Broggini
Journal:  Exp Cell Res       Date:  1998-05-25       Impact factor: 3.905

9.  Critical role for the 310 helix region of p57(Kip2) in cyclin-dependent kinase 2 inhibition and growth suppression.

Authors:  Y Hashimoto; K Kohri; Y Kaneko; H Morisaki; T Kato; K Ikeda; M Nakanishi
Journal:  J Biol Chem       Date:  1998-06-26       Impact factor: 5.157

10.  Induction of p53-dependent and p53-independent cellular responses by topoisomerase 1 inhibitors.

Authors:  A C McDonald; R Brown
Journal:  Br J Cancer       Date:  1998-09       Impact factor: 7.640

View more
  28 in total

1.  Bcl-2 activates a programme of premature senescence in human carcinoma cells.

Authors:  Elvira Crescenzi; Giuseppe Palumbo; Hugh J M Brady
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

2.  Transcriptional upregulation of p57 (Kip2) by the cyclin-dependent kinase inhibitor BMS-387032 is E2F dependent and serves as a negative feedback loop limiting cytotoxicity.

Authors:  Y Ma; W D Cress
Journal:  Oncogene       Date:  2006-12-18       Impact factor: 9.867

Review 3.  Functional role of cellular senescence in biliary injury.

Authors:  Luke Meng; Morgan Quezada; Phillip Levine; Yuyan Han; Kelly McDaniel; Tianhao Zhou; Emily Lin; Shannon Glaser; Fanyin Meng; Heather Francis; Gianfranco Alpini
Journal:  Am J Pathol       Date:  2015-01-22       Impact factor: 4.307

Review 4.  Convergence of therapy-induced senescence (TIS) and EMT in multistep carcinogenesis: current opinions and emerging perspectives.

Authors:  Mir Mohd Faheem; Nathan D Seligson; Syed Mudabir Ahmad; Reyaz Ur Rasool; Sumit G Gandhi; Madhulika Bhagat; Anindya Goswami
Journal:  Cell Death Discov       Date:  2020-06-15

5.  Cell cycle arrest by human cytomegalovirus 86-kDa IE2 protein resembles premature senescence.

Authors:  Emanuela Noris; Claudia Zannetti; Anna Demurtas; John Sinclair; Marco De Andrea; Marisa Gariglio; Santo Landolfo
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

6.  Altered patterns of cellular gene expression in dermal microvascular endothelial cells infected with Kaposi's sarcoma-associated herpesvirus.

Authors:  Lynn J Poole; Yanxing Yu; Peter S Kim; Qi-Zhi Zheng; Jonathan Pevsner; Gary S Hayward
Journal:  J Virol       Date:  2002-04       Impact factor: 5.103

Review 7.  Cip/Kip cell-cycle inhibitors: a neuro-oncological perspective.

Authors:  T G Mainprize; M D Taylor; J T Rutka; P B Dirks
Journal:  J Neurooncol       Date:  2001-02       Impact factor: 4.130

8.  Patterns of p57Kip2 expression in embryonic rat brain suggest roles in progenitor cell cycle exit and neuronal differentiation.

Authors:  Weizhen Ye; Georges Mairet-Coello; Elise Pasoreck; Emanuel Dicicco-Bloom
Journal:  Dev Neurobiol       Date:  2009-01       Impact factor: 3.964

9.  Inducible expression of p57KIP2 inhibits glioma cell motility and invasion.

Authors:  K Sakai; A Peraud; T Mainprize; J Nakayama; A Tsugu; K Hongo; S Kobayashi; James T Rutka
Journal:  J Neurooncol       Date:  2004-07       Impact factor: 4.130

10.  Imprinted CDKN1C is a tumor suppressor in rhabdoid tumor and activated by restoration of SMARCB1 and histone deacetylase inhibitors.

Authors:  Elizabeth M Algar; Andrea Muscat; Vinod Dagar; Christian Rickert; C W Chow; Jaclyn A Biegel; Paul G Ekert; Richard Saffery; Jeff Craig; Ricky W Johnstone; David M Ashley
Journal:  PLoS One       Date:  2009-02-16       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.